About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Driver

TO True, we live and learn, my big loss this year so far is Aisa Energy still suspended !! lets hope we all can make a few quid on erx : )

Doctors hail lung cancer breakthrough




28 September 2006
An experimental drug that extends the lives of lung cancer patients by a third has impressed doctors, who say that it is one of the first signs of progress against the disease.

Lung cancer is among the most lethal of all cancers and claims more lives each year than any other. Only five per cent of patients survive more than five years.

Efforts to find an effective treatment have failed and unlike other cancers, such as breast cancer, the death rate has not changed for more than a decade. A trial of the as yet unnamed drug, known as AS1404, in 70 patients with non-small cell lung cancer (NSCLC), the commonest kind, found they lived for 14 months on average compared with 8.8 months for those given chemotherapy alone.

Although the extra five months gained is small in absolute terms, it is a significant improvement, suggesting a genuine benefit from the drug. More than 26,000 people in Britain die from NSCLC each year.

The drug, discovered by researchers in New Zealand and developed by the UK biotechnology company, Antisoma, with backing from Cancer Research UK, is one of a new class of compounds called vascular disrupting agents. These work by destroying blood vessels that supply solid tumours on which the tumours depend to survive and grow.

The success of the phase II study lays the ground for a larger phase III trial, the outcome of which will determine whether the drug is licensed as safe and effective. AS1404 has already been shown to be effective in phase II trials of prostate and ovarian cancer.

Mark McKeage of the University of Auckland, one of the researchers, said: "It is great to see this large survival benefit with AS1404 in lung cancer patients. This makes me feel very optimistic as we progress into phase III testing."

Professor Alex Markham, chief executive of Cancer Research UK, said: "Our drug development team played an integral role in the early development of the drug and we're delighted with this news. We look forward to seeing how the drug performs in a much larger number of patients."

The charity has set up a company to raise the number of undeveloped new treatments by putting them into clinical trials. Since 1982, more than 100 agents have been put into trials.

"Over the next five years we plan to double our activity and speed up the drug development process, getting even more new drugs into clinical trials," Professor Markham said.

* Living near heavy industry may raise the risk of lung cancer. A study of women in Teesside, who lived within three miles of a chemical production complex at Billingham for at least 25 years, found they were twice as likely to develop the disease than others, after smoking and other factors were taken into account.
http://www.belfasttelegraph.co.uk/lifestyle/health_beauty/story.jsp?story=708067

Sonus Pharmaceuticals Initiates Phase 1 Clinical Trial for ...
Genetic Engineering News (press release), NY - 1 hour ago
... "This promising compound may have the ... lead oncology product candidate, TOCOSOL Paclitaxel, is currently in a Phase 3 pivotal trial in metastatic breast cancer. ...

Biothera Completes Second Phase I Clinical Trial for Cancer Drug
PipelineReview.com (press release), Spain - 6 hours ago
... I clinical trial for Imprime PGG its lead compound for activating ... and increases in survival in multiple types of cancer, including breast, lung and ...

All buys again today you can buy online at 28 so all buys.

Correction one sell at 25

so they knock it down.. rediculous

That was a short post PH

must be news tomorrow then ;-)

PH
You have worn yourself out go and have a rest.

5m buys at the end of day, news on monday?

Hi Driver, one of those was mine (1m), no reason other than it seemed a good time to top up! Still very speculative but it looks like things are moving in the right direction. Let's hope we have a bit of luck with this one!
kim

kim
Hi kim clad to see you are still in and topping up, yes it does seem more promising than when we first invested our patience on this one might reap us a multi bagger.

10 million buys x 2 and a couple of 3 million earlier.

laurie squash
Cheers laurie a couple of big buys gone through some one is confident in ERX I know you have posted on here before are you in or out welcome aboard if you are.

could be news soon (with in 3 weeks may be ?) Driver some good buys but no change in the SP ???????????

Driver

Hi yes in but in a small way waiting for GOO to happen! So spread a bit thin.

laurie, a holding is a holding , I only have 250000 but still we all could make on this if good news soon ! :)

does this sound like the results of ERX or what, I suspect this is the partner they are in negotiations with, that or they have commited industrial espionage

EpiCept Announces IND Filing of Novel Compound with Potent Apoptotic and Tumor Selective Vascular Disruptive Activity for Treatment of Cancer
EPC2407 Latest Clinical Candidate from Company's Apoptosis Screening Technology


ENGLEWOOD CLIFFS, N.J., Oct. 2 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq: EPCT; OMX Stockholm) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin Phase I clinical studies of EPC2407 in cancer patients. EPC2407 is the Company's novel small molecule which induces apoptosis (cell death) and disruption of tumor blood flow. EPC2407 is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors include the frequently occurring cancers of the lung, ovaries, and breast. These cancers still have a high mortality rate despite progress in earlier stages of these diseases.

EPC2407 is the first of a new class of microtubulin inhibitors which cause cell cycle arrest, caspase activation and apoptotic death in cancer cells. The compound has demonstrated in pre-clinical studies potent anti-tumor activity against a number of tumor types and is synergistic with cisplatin. EPC2407 also disrupts the vasculature of tumor blood vessels leading to hypoxia and tumor necrosis. This has been shown to occur in pre-clinical studies in tumored animals at subtoxic concentrations. The objectives of this first clinical trial of EPC2407 is to determine the maximum tolerated dose, to characterize the blood levels and biological effects of the drug and to identify any anti-tumor response as measured by CT scans, MRI or PET scans. The study is expected to enroll approximately 30-40 patients.

One of the investigators for this study is Dr. Daniel von Hoff from the Center for Translational Drug Development, TGen, the Scottsdale Healthcare Clinical Research Institute and the Arizona Cancer Center. Dr. von Hoff commented, "We are pleased to work with EpiCept Corporation to test this potential new anti-cancer compound in patients with advanced cancers. Results from pre-clinical testing of EPC2407 are encouraging, and mechanism studies suggest two ways that this new agent may add to our treatment options for a range of cancers."

"The filing of an IND for EPC2407 represents an important milestone for our company," stated Jack Talley, President and Chief Executive Officer. "We believe this filing deepens our already promising clinical pipeline of pain and cancer treatment candidates and further demonstrates the potential of our proprietary apoptosis screening technology which led to the discovery and development of EPC2407. This compound represents the second clinical cancer candidate discovered by EpiCept researchers utilizing this technology. We have identified several other promising compounds with the potential for further development which we intend to selectively pursue. Our goal is to progress these product candidates into clinical development and seek partners prior to the commencement of pivotal scale trials."

About EPC2407

The IND filing for EPC2407 is based on the compound's effectiveness in several pre-clinical animal models of cancer and its potent anti-tumor effects both in vitro and in vivo. Nanomolar concentrations of the molecule have been shown to induce tumor cell apoptosis and to selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated that EPC2407 inhibits growth of established tumors of a number of different cancer types. The safety profile of the compound in standard toxicology studies also supports its testing in human clinical trials.

Pre-clinical studies suggest that the anti-tumor effects of EPC2407 may be the result of a dual mechanism, a direct effect of tumor apoptosis and a second effect on disruption of tumor vascular endothelial cells leading to hypoxia and central tumor necrosis, as observed with vascular disruption agents.

About EpiCept's Apoptosis Screening Technology

Cancer cells often exhibit unchecked growth caused by the disabled or absent natural process of programmed cell death called apoptosis. Apoptosis is a normal process of triggering destruction of cells from within when they have outlived their purpose or may be seriously damaged, but cancer cells grow out of control when the normal apoptosis process is not functioning. A promising approach in the fight against cancer is selective induction of or restoration of apoptosis, thereby checking, and perhaps reversing, the improper cell growth.

EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology. Chemical genetics is a research approach investigating the effect of small molecule drug candidates based on the cellular activity of a protein, enabling researchers to determine the protein's function. With the combination of chemical genetics and caspase-3 screening, EpiCept's researchers identify and test the effect of small molecules on pathways and molecular targets crucial to apoptosis and gain insights into their potential as new anticancer agents. The Company's screening technology is particularly versatile and can be adapted for many cell types that can be cultured, and it can measure caspase activation inside multiple cell types (e.g. cancer cells, immune cells, or cell lines from different organ systems or genetically engineered cells). This allows researchers to find potential drug candidates that are selective for specific cancer types, which may help identify candidates that provide increased therapeutic benefit and reduced toxicity.

EpiCept's drug discovery and pre-clinical development groups include high throughput screening (HTS) and informatics, cell biology, medicinal chemistry, and in vivo pharmacology. The HTS group identifies the hits which upon passing certain criteria are analoged by the chemistry group for secondary and tertiary assay testing by the cell biology group. Promising leads are tested in animal models for toxicity, efficacy and pharmacokinetics. An iterative interaction between the various groups provides for the rapid advancement from hit compounds to lead candidates suitable for further development.

About EpiCept Corporation

EpiCept is an emerging specialty pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The Company has a staged portfolio of product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound will be submitted in Europe in the near future. EpiCept is based in New Jersey, and the Company's research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
http://sev.prnewswire.com/medical-pharmaceuticals/20061002/NYM20402102006-1.html

http://sev.prnewswire.com/medical-pharmaceuticals/20061002/NYM20402102006-1.html

FILL YA BOOTS, THIS IS GOING TO BE HUGE

not sure, same sort of research though !!

same results as well, thats our partner, wonder how much dosh we got